Sichuan Baili Pharmaceutical Co., Ltd. clinical trial pipeline

5 trials changed in the last 30 days: 0 stopped, 5 with notable changes, 0 with minor changes only.

1. Notable

   BL-B01D1 in Combination With Osimertinib Mesylate Tablets…BL-B01D1 in Combination With Osimertinib Mesylate Tablets · Locally Advanced or Metastatic Non-small Cell Lung Cancer

   Primary and study completion pushed from Aug 2026 to Jun 2027

   Also in this update: Enrollment closed, study ongoing; Final enrollment: 76 participants (planned 40)

   Sichuan Baili Pharmaceutical Co., Ltd.·Phase 2· NCT06498986· Registry history of NCT06498986 on ClinicalTrials.gov (opens the registry)

   Oct 9, 2026

2. Notable

   BL-M08D · Locally Advanced or Metastatic Digestive Tract Tumors…BL-M08D · Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors

   Recruitment opened

   Sichuan Baili Pharmaceutical Co., Ltd.·Phase 1/2· NCT07780318· Registry history of NCT07780318 on ClinicalTrials.gov (opens the registry)

   Oct 13, 2026

3. Notable

   BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus…BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody · Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04)

   Recruitment opened

   Sichuan Baili Pharmaceutical Co., Ltd.·Phase 3· NCT07729956· Registry history of NCT07729956 on ClinicalTrials.gov (opens the registry)

   Sep 30, 2026

4. Notable

   SI-B036 · Locally Advanced or Metastatic Head and Neck Tumors and…SI-B036 · Locally Advanced or Metastatic Head and Neck Tumors and Other Solid Tumors

   Recruitment opened

   Sichuan Baili Pharmaceutical Co., Ltd.·Phase 1· NCT07763639· Registry history of NCT07763639 on ClinicalTrials.gov (opens the registry)

   Oct 1, 2026

5. Notable

   BL-ARC002 · Locally Advanced or Metastatic Gastrointestinal…BL-ARC002 · Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors

   Recruitment opened

   Sichuan Baili Pharmaceutical Co., Ltd.·Phase 1· NCT07763652· Registry history of NCT07763652 on ClinicalTrials.gov (opens the registry)

   Sep 22, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.